Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov Disord Subsets: MEDLINE

Publication: <2001->: New York, NY : Wiley-Liss
Original Publication: [New York, N.Y.] : Raven Press, [c1986-

Parkinson Disease*/epidemiology ; Parkinson Disease*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Diabetes Mellitus, Type 2*/drug therapy ; Glucagon-Like Peptide-1 Receptor*/agonists ; Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use ; Medicare*; Humans ; Male ; Aged ; Female ; Cohort Studies ; Aged, 80 and over ; United States/epidemiology ; Hypoglycemic Agents/therapeutic use ; Glucagon-Like Peptide-1 Receptor Agonists

Background: Previous studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a disease-modifying effect in the development of Parkinson's disease (PD), but population studies yielded inconsistent results.
Objective: The aim was to compare the risk of PD associated with GLP-1RAs compared to dipeptidyl peptidase 4 inhibitors (DPP4i) among older adults with type 2 diabetes (T2D).
Methods: Using U.S. Medicare administrative data from 2016 to 2020, we conducted a population-based cohort study comparing the new use of GLP-1RA with the new use of DPP4i among adults aged ≥66 years with T2D. The primary endpoint was a new diagnosis of PD. A stabilized inverse probability of treatment weighting (sIPTW)-adjusted Cox proportional hazards regression model was employed to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for PD between GLP-1RA and DPP4i users.
Results: This study included 89,074 Medicare beneficiaries who initiated either GLP-1RA (n = 30,091) or DPP4i (n = 58,983). The crude incidence rate of PD was lower among GLP-1RA users than DPP4i users (2.85 vs. 3.92 patients per 1000 person-years). An sIPTW-adjusted Cox model showed that GLP-1RA users were associated with a 23% lower risk of PD than DPP4i users (HR, 0.77; 95% CI, 0.63-0.95). Our findings were largely consistent across different subgroup analyses such as sex, race, and molecular structure of GLP-1RA.
Conclusion: Among Medicare beneficiaries with T2D, the new use of GLP-1RAs was significantly associated with a decreased risk of PD compared to the new use of DPP4i. © 2024 International Parkinson and Movement Disorder Society.
(© 2024 International Parkinson and Movement Disorder Society.)

NPJ Parkinsons Dis. 2023 Jan 27;9(1):11. (PMID: 36707543)
Stat Med. 2017 Nov 30;36(27):4391-4400. (PMID: 28913837)
Mov Disord. 2009 Jan 15;24(1):51-6. (PMID: 18816696)
Brain. 2020 Oct 1;143(10):3067-3076. (PMID: 33011770)
NPJ Parkinsons Dis. 2020 Jul 9;6:15. (PMID: 32665974)
Lancet Neurol. 2024 Jan;23(1):37-45. (PMID: 38101901)
Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: 28693043)
J Parkinsons Dis. 2014;4(3):337-44. (PMID: 24662192)
Mol Neurobiol. 2023 Aug;60(8):4547-4573. (PMID: 37118323)
Prog Neurobiol. 2017 Aug;155:57-75. (PMID: 27107797)
J Clin Invest. 2013 Jun;123(6):2730-6. (PMID: 23728174)
J Am Geriatr Soc. 2023 Jul;71(7):2041-2045. (PMID: 37227136)
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. (PMID: 38078590)
Eur Heart J. 2023 Oct 14;44(39):4043-4140. (PMID: 37622663)
Ageing Res Rev. 2023 Aug;89:101979. (PMID: 37328112)
Brain Res. 2019 Jul 1;1714:126-132. (PMID: 30826352)
Stat Med. 2009 Nov 10;28(25):3083-107. (PMID: 19757444)
Clin Diabetes. 2020 Oct;38(4):363-370. (PMID: 33132506)
Stat Med. 2014 May 10;33(10):1685-99. (PMID: 24323618)
Am J Epidemiol. 2018 Sep 1;187(9):1951-1961. (PMID: 29750409)
J Parkinsons Dis. 2018;8(2):247-258. (PMID: 29843254)
JAMA Netw Open. 2020 Oct 1;3(10):e2020969. (PMID: 33057641)
Diabet Med. 2019 Jun;36(6):688-701. (PMID: 30672017)
Neurochem Int. 2019 Dec;131:104583. (PMID: 31654678)
Mov Disord. 2016 Sep;31(9):1422-3. (PMID: 27431803)
Neurology. 2020 Nov 3;95(18):e2500-e2508. (PMID: 32943485)
Neurotox Res. 2019 Apr;35(3):635-653. (PMID: 30673988)
Neuropeptides. 2018 Oct;71:70-80. (PMID: 30017231)
Inflammopharmacology. 2017 Jun;25(3):369-382. (PMID: 28258522)
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3463-8. (PMID: 25733901)
J Clin Diagn Res. 2016 Oct;10(10):YE01-YE06. (PMID: 27891446)
Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):875-882. (PMID: 35505634)
Diabetes Obes Metab. 2018 Apr;20(4):974-984. (PMID: 29206336)
Sci Rep. 2023 Dec 15;13(1):22489. (PMID: 38110464)
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76. (PMID: 18344392)
Value Health. 2010 Mar-Apr;13(2):273-7. (PMID: 19912596)
Neurol Sci. 2023 Dec;44(12):4193-4203. (PMID: 37500992)
Lancet. 2017 Oct 7;390(10103):1664-1675. (PMID: 28781108)
Curr Epidemiol Rep. 2015 Dec;2(4):221-228. (PMID: 26954351)
Front Neurol. 2021 Jul 19;12:678649. (PMID: 34349721)
N Engl J Med. 2024 Apr 4;390(13):1176-1185. (PMID: 38598572)
BMC Neurosci. 2012 Mar 23;13:33. (PMID: 22443187)
Cells. 2020 Mar 17;9(3):. (PMID: 32192190)

R01 DK133465 United States DK NIDDK NIH HHS; American Foundation for Pharmaceutical Education; Pharmaceutical Research and Manufacturers of America Foundation; R01DK133465 United States DK NIDDK NIH HHS; R01DK133465 United States DK NIDDK NIH HHS

Keywords: Parkinson's disease; dipeptidyl peptidase 4 inhibitor (DPP4i); glucagon‐like peptide‐1 receptor agonist (GLP‐1RA); type 2 diabetes

0 (Glucagon-Like Peptide-1 Receptor)
0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Hypoglycemic Agents)
0 (Glucagon-Like Peptide-1 Receptor Agonists)

Date Created: 20240827 Date Completed: 20241116 Latest Revision: 20241118

20241118

PMC11568939

10.1002/mds.29992

39189078